Industry analysts continue to posit that biotechnology consolidation is poised to accelerate through year-end – a scenario that could propel the ALPS Medical Breakthroughs ETF (SBIO) further forward. While there’s frequent chatter about biotechnology mergers and acquisitions, particularly...